Annual Review 2021

This year The Royal Marsden NHS Foundation Trust continued to ensure cancer patients at the hospital, across the UK and around the world can benefit from the advances being made in cancer research, treatment and care.

Download the full report to read the Chairman and Chief Executive joint statement.

Read the statement

Who we are and what we do

Research

The complexity of cancer is a constant challenge. The Royal Marsden, alongside The Institute of Cancer Research, utilises an ambitious, patient‑centred approach that recognises this complexity and develops smarter, kinder treatments for the benefit of cancer patients worldwide.

Diagnosis

Early diagnosis is crucial to improving survival for cancer patients, and is vital for the research of cancer. Together with RM Partners, we are committed to improving early diagnosis rates, reducing variation in outcomes and increasing capacity to ensure swift diagnosis of cancer for patients.

Treatment

Patients at The Royal Marsden receive personalised treatment relating to their diagnosis. With innovative equipment including the latest in robotic surgery, radiotherapy and genomics, we ensure every patient has access to the very best treatment through every stage of their cancer journey.

Care

It is vital that the emotional and psychological needs of patients are met throughout their cancer treatment, which is why staff at The Royal Marsden treat the whole person, not just their illness, with a compassionate, caring approach for them and their friends and family.

 

Our achievements

See the full picture

The Royal Marsden became the first hospital in the UK to open an innovative clinical trial (ESMART) to test the benefits of treatment combinations that were previously unavailable for children and young people

A rapid digital transformation programme was put in place to change the way the Trust provided healthcare, to ensure the safety of patients and staff during the COVID-19 pandemic, including virtual consultations and remote monitoring

The Royal Marsden Private Care opened a new research‑led diagnostic and treatment facility in Cavendish Square in April 2021, offering patients fast and direct access to experts whilst further enhancing care provision

Royal Marsden researchers launched several COVID‑19 studies at pace, including the CAPTURE study aimed at understanding the biology and interactions between COVID‑19, immunity, cancer and cancer treatment

The Royal Marsden and RM Partners were the first to establish a Cancer Surgical Hub during the first peak of the COVID-19 pandemic, to provide patients with access to urgent cancer surgery. This model was later rolled out nationally due to its success.

Building work started for the Oak Cancer Centre, a new five-floor cancer research and treatment facility at Sutton, which will enable The Royal Marsden to save more lives by diagnosing cancer earlier and speeding up the development of new treatments.

The Royal Marsden Cancer Charity’s COVID‑19 emergency appeal raised £2 million and funded initiatives including mental wellbeing and psychological support for staff and patients, and research studies to investigate the impact of COVID -19 on cancer patients.

RM Medicines was launched – a new ‘wholly owned subsidiary’ to provide pharmacy outpatient services. This model will provide a platform for a cohesive and responsive pharmacy service across The Royal Marsden.

 
Treatment and Care

Our highlights

Research and innovation

  • The Royal Marsden is the first hospital in the UK to open an innovative clinical trial, ESMART, to test the benefits of treatment combinations that were previously unavailable for children and young people.

  • The results of the monarchE study were presented at the European Society for Medical Oncology. The study found that the drug abemaciclib – one of a new generation of treatments known as CDK 4/6 inhibitors – reduced the risk of cancer recurrence in patients with early-stage hormone receptor positive (HR+) breast cancer. This represents one of the most promising breakthroughs for patients with HR+ breast cancer.

Read more on page 15

Treatment and care

  • The first patients were treated on the second CyberKnife at The Royal Marsden, Sutton - the only CyberKnife in the UK with a multi‑leaf collimator head, which means it can deliver radiation more quickly, meaning shorter treatment sessions for patients.

  • Two Royal Marsden nurses have been selected to take part in the Florence Nightingale Foundation’s Windrush Nurses and Midwives leadership programme. The course was created to celebrate medical professionals who are either descendants of the Windrush generation or from BAME background.

Read more on page 19

Modernising infrastructure

  • The Royal Marsden welcomed its President, HRH The Duke of Cambridge, to a socially distanced ground‑breaking ceremony in October 2020 to mark the start of building works for the Oak Cancer Centre, the new cancer research and treatment facility at the Sutton hospital.

  • In April 2021, The Royal Marsden Private Care opened a new research‑led diagnostic and treatment facility in Cavendish Square, central London. The new outpatient centre offers fast and direct access to experts in a high -quality environment.

Read more on page 23

Financial stability and best value

  • In September 2020, RM Medicines was launched – a new ‘wholly owned subsidiary’ to provide pharmacy outpatient services. This model will bring significant benefits to patients, including providing direct support to care closer to home initiatives and delivery of oral chemotherapy to patients' homes.

  • This year saw huge progress in terms of the innovative digital tools deployed to enable home working at scale, patient ‘virtual visits’ and to support remote clinical and research collaboration.

Read more on page 27

Response to COVID-19

  • The Royal Marsden and RM Partners, the Cancer Alliance for west London, established a Cancer Surgical Hub during the first peak of the COVID‑19 pandemic, to provide patients with access to urgent cancer surgery. Since the country initially went into lockdown in March 2020, over 7,000 patients were able to access urgent cancer surgery through the Hub.

Read more on page 30

The Royal Marsden Cancer Charity

The Royal Marsden Cancer Charity raises money solely to support The Royal Marsden, a world‑leading cancer centre. They ensure our nurses, doctors and research teams can provide the very best care and develop life‑saving treatments, which are used across the UK and around the world.

Since its launch, the Charity has raised £65 million towards a £70 million appeal for the Oak Cancer Centre, a new treatment and research facility adjacent to The Royal Marsden hospital in Sutton.

The Charity also enabled the hospital to install its second CyberKnife radiotherapy machine, which began treating patients in the summer of 2020.

The Charity’s supporters found imaginative ways to fundraise from their own homes and embraced virtual versions of traditional events and new virtual events. Thanks to these dedicated supporters, The Royal Marsden Cancer Charity was able to grant the hospital an incredible £10.98 million in 2020/21.

Our values

The Royal Marsden brand is shaped by a distinct set of values that define what we are and how we behave.

Pioneering
Change

We lead the way in cancer research and drive continuous innovation to improve the lives of patients.

Working
Collaboratively

We work in an inclusive way, bringing together different expertise, partners and resources to achieve the best possible outcomes.

Pursuing
Excellence

We strive to be experts in our field, working to deliver outstanding quality in all that we do.

Showing
Kindness

We aspire to create a world‑class experience where all patients, staff and partners feel valued and respected.

Read the Annual Review and Report in full

View